Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB‐756050, in Type 2 Diabetes
Publication
, Journal Article
Hodge, RJ; Lin, J; Vasist Johnson, LS; Gould, EP; Bowers, GD; Nunez, DJ
Published in: Clinical Pharmacology in Drug Development
July 2013
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Clinical Pharmacology in Drug Development
DOI
EISSN
2160-7648
ISSN
2160-763X
Publication Date
July 2013
Volume
2
Issue
3
Start / End Page
213 / 222
Publisher
Wiley
Citation
APA
Chicago
ICMJE
MLA
NLM
Hodge, R. J., Lin, J., Vasist Johnson, L. S., Gould, E. P., Bowers, G. D., & Nunez, D. J. (2013). Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB‐756050, in Type 2 Diabetes. Clinical Pharmacology in Drug Development, 2(3), 213–222. https://doi.org/10.1002/cpdd.34
Hodge, Rebecca J., Jiang Lin, Lakshmi S. Vasist Johnson, Elizabeth P. Gould, Gary D. Bowers, and Derek J. Nunez. “Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB‐756050, in Type 2 Diabetes.” Clinical Pharmacology in Drug Development 2, no. 3 (July 2013): 213–22. https://doi.org/10.1002/cpdd.34.
Hodge RJ, Lin J, Vasist Johnson LS, Gould EP, Bowers GD, Nunez DJ. Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB‐756050, in Type 2 Diabetes. Clinical Pharmacology in Drug Development. 2013 Jul;2(3):213–22.
Hodge, Rebecca J., et al. “Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB‐756050, in Type 2 Diabetes.” Clinical Pharmacology in Drug Development, vol. 2, no. 3, Wiley, July 2013, pp. 213–22. Crossref, doi:10.1002/cpdd.34.
Hodge RJ, Lin J, Vasist Johnson LS, Gould EP, Bowers GD, Nunez DJ. Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB‐756050, in Type 2 Diabetes. Clinical Pharmacology in Drug Development. Wiley; 2013 Jul;2(3):213–222.
Published In
Clinical Pharmacology in Drug Development
DOI
EISSN
2160-7648
ISSN
2160-763X
Publication Date
July 2013
Volume
2
Issue
3
Start / End Page
213 / 222
Publisher
Wiley